Journal Wrap | BPROAD: Intensive BP Control in Type 2 Diabetes; SUMMIT; More
The hottest research from various peer-reviewed journals – handpicked weekly by the ACC.org Editorial Board led by Kim A. Eagle, MD, MACC.
BPROAD: Support For Intensive BP Control in Type 2 Diabetes
Intensive treatment to control systolic blood pressure (SBP) to <120 mm Hg significantly reduced the incidence of major cardiovascular events in patients over the age of 50 with type 2 diabetes (T2D), based on results from the BPROAD trial presented at AHA 2024 and simultaneously published in the NEJM.
SUMMIT: Tirzepatide Improves Outcomes, QOL in Patients With HFpEF and Obesity
In patients with obesity and heart failure with preserved ejection fraction (HFpEF), weekly treatment with tirzepatide over approximately two years reduced the risk of worsening HF events, based on findings from the SUMMIT trial presented at AHA 2024 and simultaneously published in NEJM. Study authors also noted improvements in health status and exercise tolerance.
Keywords: Cardiology Magazine, ACC Publications, Diabetes Mellitus, Type 2, Blood Pressure, Antihypertensive Agents, Obesity, Heart Failure, Preserved Ejection Fraction
